Quarterly report pursuant to Section 13 or 15(d)

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

v3.21.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS        
Revenue $ 0 $ 0 $ 0 $ 0
Operating Expenses        
General and administrative 1,763,060 2,835,471 5,061,820 6,800,892
Research and development 439,630 261,898 1,082,394 767,498
Total Operating Expenses 2,202,690 3,097,369 6,144,214 7,568,390
Other Operating Income        
Distribution from joint venture 0 0 110,000 0
Grant income 288,884 29,662 459,997 29,662
Total Other Operating Income 288,884 29,662 569,997 29,662
Operating Loss (1,913,806) (3,067,707) (5,574,217) (7,538,728)
Other Income        
Interest income 1,551 4,645 6,183 79,474
Foreign currency transaction gain 0 0 0 33,694
Total Other Income 1,551 4,645 39,877 79,474
Net Loss Before Income Taxes (1,912,255) (3,063,062) (5,534,340) (7,459,254)
Income taxes 0 0 0 0
Net Loss (1,912,255) (3,063,062) (5,534,340) (7,459,254)
Accumulated preferred stock dividend (135,091) (128,937) (399,838) (383,086)
Deemed additional dividend on preferred stock dividend due to the beneficial conversion feature (59,314) (55,940) (175,211) (165,551)
Net loss attributable to common stockholders $ (2,106,660) $ (3,247,939) $ (6,109,389) $ (8,007,891)
Net Loss Per Common Share, Basic and Diluted $ (0.31) $ (0.80) $ (0.92) $ (2.22)
Weighted Average Number of Common Shares Outstanding 6,759,662 4,053,644 6,648,803 3,613,349